SynthesisTheranostics2021
Treatment of severe acute respiratory syndrome (SARS), Middle East respiratory syndrome (MERS), and coronavirus disease 2019 (COVID-19): a systematic review of
Synthesis in Theranostics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Does colchicine reduce mortality in patients with COVID-19 clinical syndrome? An umbrella review of published meta-analyses.Heliyon · 2023Review
- A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.Heliyon · 2023Review
- Potential RNA-dependent RNA polymerase (RdRp) inhibitors as prospective drug candidates for SARS-CoV-2.European journal of medicinal chemistry · 2023Review
- Assessment of drugs administered in the Middle East as part of the COVID-19 management protocols.Inflammopharmacology · 2022Review
- An update on inhibitors targeting RNA-dependent RNA polymerase for COVID-19 treatment: Promises and challenges.Biochemical pharmacology · 2022Review
- In vitro antiviral effects of GS-441524 and itraconazole combination against feline infectious peritonitis virus.Research in veterinary science · 2022Article
- A dual mechanism of action of AT-527 against SARS-CoV-2 polymerase.Nature communications · 2022Article
- Cardiovascular events and safety outcomes associated with remdesivir using a World Health Organization international pharmacovigilance database.Clinical and translational science · 2022Article
- Age and genotype dependent erythropoietin protection in COVID-19.World journal of stem cells · 2021Review
- Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews.Diagnostics (Basel, Switzerland) · 2021Review
- Contemporary narrative review of treatment options for COVID-19.Respirology (Carlton, Vic.) · 2021Review
- Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs.Biomedicines · 2021Article
- Immunotherapy for COVID-19: Evolving treatment of viral infection and associated adverse immunological reactions.Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis · 2021Review
- The COVID-19 Treatment Landscape: A South African Perspective on a Race Against Time.Frontiers in medicine · 2021Review
- Binary-QSAR guided virtual screening of FDA approved drugs and compounds in clinical investigation against SARS-CoV-2 main protease.Turkish journal of biology = Turk biyoloji dergisi · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.